121 related articles for article (PubMed ID: 9175901)
1. Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity.
Siegan JB; Hama AT; Sagen J
Brain Res; 1997 May; 755(2):331-4. PubMed ID: 9175901
[TBL] [Abstract][Full Text] [Related]
2. NMDA-induced spinal hypersensitivity is reduced by naturally derived peptide analog [Ser1]histogranin.
Hama AT; Siegan JB; Herzberg U; Sagen J
Pharmacol Biochem Behav; 1999 Jan; 62(1):67-74. PubMed ID: 9972847
[TBL] [Abstract][Full Text] [Related]
3. Selective antihyperalgesic effect of [Ser1] histogranin on complete Freund's adjuvant-induced hyperalgesia in rats.
Hama A; Sagen J
Pain; 2002 Jan; 95(1-2):15-21. PubMed ID: 11790463
[TBL] [Abstract][Full Text] [Related]
4. NMDA antagonist peptide supplementation enhances pain alleviation by adrenal medullary transplants.
NasiriNezhad F; Sagen J
Cell Transplant; 2005; 14(4):203-11. PubMed ID: 15929555
[TBL] [Abstract][Full Text] [Related]
5. Viral vectors encoding endomorphins and serine histogranin attenuate neuropathic pain symptoms after spinal cord injury in rats.
Nasirinezhad F; Gajavelli S; Priddy B; Jergova S; Zadina J; Sagen J
Mol Pain; 2015 Jan; 11():2. PubMed ID: 25563474
[TBL] [Abstract][Full Text] [Related]
6. Functional interaction between N-methyl-D-aspartate receptor and ascorbic acid during neuropathic pain induced by chronic constriction injury of the sciatic nerve.
Saffarpour S; Nasirinezhad F
J Basic Clin Physiol Pharmacol; 2017 Nov; 28(6):601-608. PubMed ID: 28902622
[TBL] [Abstract][Full Text] [Related]
7. Effect of pre-emptive NMDA antagonist treatment on long-term Fos expression and hyperalgesia in a model of chronic neuropathic pain.
Munglani R; Hudspith MJ; Fleming B; Harrisson S; Smith G; Bountra C; Elliot PJ; Birch PJ; Hunt SP
Brain Res; 1999 Mar; 822(1-2):210-9. PubMed ID: 10082898
[TBL] [Abstract][Full Text] [Related]
8. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain.
Qu XX; Cai J; Li MJ; Chi YN; Liao FF; Liu FY; Wan Y; Han JS; Xing GG
Exp Neurol; 2009 Feb; 215(2):298-307. PubMed ID: 19046970
[TBL] [Abstract][Full Text] [Related]
9. Effect of post-injury NMDA antagonist treatment on long-term Fos expression and hyperalgesia in a model of chronic neuropathic pain.
Hudspith MJ; Harrisson S; Smith G; Bountra C; Elliot PJ; Birch PJ; Hunt SP; Munglani R
Brain Res; 1999 Mar; 822(1-2):220-7. PubMed ID: 10082899
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain.
Roh DH; Kim HW; Yoon SY; Seo HS; Kwon YB; Kim KW; Han HJ; Beitz AJ; Na HS; Lee JH
Anesthesiology; 2008 Nov; 109(5):879-89. PubMed ID: 18946301
[TBL] [Abstract][Full Text] [Related]
11. A natural peptide with NMDA inhibitory activity reduces tonic pain in the formalin model.
Siegan JB; Sagen J
Neuroreport; 1997 Apr; 8(6):1379-81. PubMed ID: 9172139
[TBL] [Abstract][Full Text] [Related]
12. Endogenous nitric oxide inhibits spinal NMDA receptor activity and pain hypersensitivity induced by nerve injury.
Chen SR; Jin XG; Pan HL
Neuropharmacology; 2017 Oct; 125():156-165. PubMed ID: 28754372
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury.
Bennett AD; Everhart AW; Hulsebosch CE
Brain Res; 2000 Mar; 859(1):72-82. PubMed ID: 10720616
[TBL] [Abstract][Full Text] [Related]
14. Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain.
Swartjes M; Morariu A; Niesters M; Aarts L; Dahan A
Anesthesiology; 2011 Jul; 115(1):165-74. PubMed ID: 21606828
[TBL] [Abstract][Full Text] [Related]
15. N-methyl-D-aspartate Receptors in the Prelimbic Cortex are Critical for the Maintenance of Neuropathic Pain.
Medeiros P; Negrini-Ferrari SE; Palazzo E; Maione S; Ferreira SH; de Freitas RL; Coimbra NC
Neurochem Res; 2019 Sep; 44(9):2068-2080. PubMed ID: 31317507
[TBL] [Abstract][Full Text] [Related]
16. N-methyl-D-aspartate receptor-mediated modulations of the anti-allodynic effects of 5-HT1B/1D receptor stimulation in a rat model of trigeminal neuropathic pain.
Kayser V; Latrémolière A; Hamon M; Bourgoin S
Eur J Pain; 2011 May; 15(5):451-8. PubMed ID: 20965753
[TBL] [Abstract][Full Text] [Related]
17. Combinations of intrathecal gamma-amino-butyrate receptor agonists and N-methyl-d-aspartate receptor antagonists in rats with neuropathic spinal cord injury pain.
Hama A; Sagen J
Eur J Pharmacol; 2012 May; 683(1-3):101-8. PubMed ID: 22449374
[TBL] [Abstract][Full Text] [Related]
18. Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model.
Nakazato E; Kato A; Watanabe S
Pharmacology; 2005 Jan; 73(1):8-14. PubMed ID: 15452358
[TBL] [Abstract][Full Text] [Related]
19. Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models.
Kim Y; Cho HY; Ahn YJ; Kim J; Yoon YW
Pain; 2012 May; 153(5):1022-1029. PubMed ID: 22424878
[TBL] [Abstract][Full Text] [Related]
20. Respective pharmacological features of neuropathic-like pain evoked by intrathecal BDNF versus sciatic nerve ligation in rats.
M'Dahoma S; Barthélemy S; Tromilin C; Jeanson T; Viguier F; Michot B; Pezet S; Hamon M; Bourgoin S
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2118-30. PubMed ID: 26343858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
